Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jules P P Meijerink"'
Autor:
Yunlei Li, Jessica G C A M Buijs-Gladdines, Kirsten Canté-Barrett, Andrew P Stubbs, Eric M Vroegindeweij, Willem K Smits, Ronald van Marion, Winand N M Dinjens, Martin Horstmann, Roland P Kuiper, Rogier C Buijsman, Guido J R Zaman, Peter J van der Spek, Rob Pieters, Jules P P Meijerink
Publikováno v:
PLoS Medicine, Vol 13, Iss 12, p e1002200 (2016)
Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood cancer and the leading cause of cancer-related mortality in children. T cell ALL (T-ALL) represents about 15% of pediatric ALL cases and is considered a high-risk disease. T-AL
Externí odkaz:
https://doaj.org/article/1fa50ae1f8024b568b22d5497f9e3a8f
Autor:
Emma Kroeze, Michelle M. Kleisman, Lennart A. Kester, Marijn A. Scheijde‐Vermeulen, Edwin Sonneveld, Jessica G. C. Buijs‐Gladdines, Melanie M. Hagleitner, Friederike A. G. Meyer‐Wentrup, Margreet A. Veening, Auke Beishuizen, Jules P. P. Meijerink, Jan L. C. Loeffen, Roland P. Kuiper
Publikováno v:
HemaSphere, Vol 8, Iss 7, Pp n/a-n/a (2024)
Abstract Twenty percent of children with T‐cell lymphoblastic lymphoma (T‐LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low‐risk subgroup in pediatric T‐LBL, yet these high‐risk patients who
Externí odkaz:
https://doaj.org/article/f691a15ba3c94664ba8c567a4dea1811
Autor:
Sarah J Stein, Ethan A Mack, Kelly S Rome, Kostandin V Pajcini, Takuya Ohtani, Lanwei Xu, Yunlei Li, Jules P P Meijerink, Robert B Faryabi, Warren S Pear
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155408 (2016)
Trib2 is highly expressed in human T cell acute lymphoblastic leukemia (T-ALL) and is a direct transcriptional target of the oncogenic drivers Notch and TAL1. In human TAL1-driven T-ALL cell lines, Trib2 is proposed to function as an important surviv
Externí odkaz:
https://doaj.org/article/4a24ef311aa44b3886fece58b3199e5d
Autor:
Elnaz Farahbakhshian, Monique M Verstegen, Trudi P Visser, Sima Kheradmandkia, Dirk Geerts, Shazia Arshad, Noveen Riaz, Frank Grosveld, Niek P van Til, Jules P P Meijerink
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e105642 (2014)
Allogeneic hematopoietic stem cell (HSC) transplantations from umbilical cord blood or autologous HSCs for gene therapy purposes are hampered by limited number of stem cells. To test the ability to expand HSCs in vitro prior to transplantation, two g
Externí odkaz:
https://doaj.org/article/582a3ab15d1841a4aa688c9dadabc450
Autor:
Emma Kroeze, Dilys D. Weijers, Michelle M. Kleisman, Uri Ilan, Reno S. Bladergroen, Rico Hagelaar, Jules P. P. Meijerink, Marjolijn C. J. Jongmans, Jan L. C. Loeffen, Roland P. Kuiper
Publikováno v:
HemaSphere, Vol 8, Iss 5, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/f06e363facb04d1f9c65581e4a74e3cd
Autor:
Machteld M Tiemessen, Miranda R M Baert, Tom Schonewille, Martijn H Brugman, Farbod Famili, Daniela C F Salvatori, Jules P P Meijerink, Ugur Ozbek, Hans Clevers, Jacques J M van Dongen, Frank J T Staal
Publikováno v:
PLoS Biology, Vol 10, Iss 11, p e1001430 (2012)
The HMG-box factor Tcf1 is required during T-cell development in the thymus and mediates the nuclear response to Wnt signals. Tcf1(-/-) mice have previously been characterized and show developmental blocks at the CD4-CD8- double negative (DN) to CD4+
Externí odkaz:
https://doaj.org/article/d01e65ab97f9410c99e8a9d22ab94577
Autor:
Miriam, Butler, Britt M T, Vervoort, Dorette S, van Ingen Schenau, Lieneke, Jongeneel, Jordy C G, van der Zwet, René, Marke, Jules P P, Meijerink, Blanca, Scheijen, Laurens T, van der Meer, Frank N, van Leeuwen
Publikováno v:
Frontiers in oncology. 12
Although long-term survival in pediatric acute lymphoblastic leukemia (ALL) currently exceeds 90%, some subgroups, defined by specific genomic aberrations, respond poorly to treatment. We previously reported that leukemias harboring deletions or muta
Autor:
Demi T C, De Winter, Jenneke E, Van Atteveld, Jessica G C A M, Buijs-Gladiness, Rob, Pieters, Sebastian J C M M, Neggers, Jules P P, Meijerink, Marry M, Van den Heuvel-Eibrink
Publikováno v:
Haematologica.
Not available.
Autor:
Valentina Cordo’, Mariska T. Meijer, Rico Hagelaar, Richard R. de Goeij-de Haas, Vera M. Poort, Alex A. Henneman, Sander R. Piersma, Thang V. Pham, Koichi Oshima, Adolfo A. Ferrando, Guido J. R. Zaman, Connie R. Jimenez, Jules P. P. Meijerink
Publikováno v:
Cordo', V, Meijer, M T, Hagelaar, R, de Goeij-de Haas, R R, Poort, V M, Henneman, A A, Piersma, S R, Pham, T V, Oshima, K, Ferrando, A A, Zaman, G J R, Jimenez, C R & Meijerink, J P P 2022, ' Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies ', Nature Communications, vol. 13, no. 1, pp. 1048 . https://doi.org/10.1038/s41467-022-28682-1
Nature Communications, 13(1)
Nature communications, 13(1):1048. Nature Publishing Group
Nature Communications, 13(1)
Nature communications, 13(1):1048. Nature Publishing Group
Protein kinase inhibitors are amongst the most successful cancer treatments, but targetable kinases activated by genomic abnormalities are rare in T cell acute lymphoblastic leukemia. Nevertheless, kinases can be activated in the absence of genetic d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bba7b21732de24faa532b8a7e537fc76
https://research.vumc.nl/en/publications/d1e49d24-e298-4768-b5a7-300e849a1ae5
https://research.vumc.nl/en/publications/d1e49d24-e298-4768-b5a7-300e849a1ae5
Autor:
Emma Kroeze, Dilys D. Weijers, Melanie M. Hagleitner, Hester A. de Groot-Kruseman, Marjolijn C. J. Jongmans, Roland P. Kuiper, Rob Pieters, Jules P. P. Meijerink, Jan L. C. Loeffen
Publikováno v:
HemaSphere, Vol 6, Iss 1, p e668 (2022)
HemaSphere
HemaSphere
This study describes the clinical characteristics of a complete Dutch T-cell lymphoblastic lymphoma (T-LBL) cohort, including second primary malignancies and comorbidities. We show that over 10% of patients in this complete T-LBL cohort have been dia